ESCR Funding Politics: It is About the Pork

Stock prices for embryonic stem cell research companies took a hit when the U.S. Senate failed to pass a bill to overturn President Bush’s stem cell funding policy by a veto proof margin. Worcester, MA’s, Advanced Cell Technology—which opened an office in California to try and take advantage of the cornicopia of Proposition 71 money—lost value, as did California’s Geron. Some adult stem cell companies also lost ground, but others gained.

Well, the market doesn’t lie: A big part of the drive to overturn Bush’s policy is pure corporate welfare pork. Sooweeee!